NASDAQ$TBPH
Theravance Biopharma Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Theravance Biopharma reported financial results for the first quarter of 2022 and provided a business update.
Theravance Biopharma reported their Q1 2022 financial results, highlighting their execution against the business plan and remaining on track to become sustainably cash-flow positive by the second half of 2022. YUPELRI's hospital sales performance and market share gains were noted. The company plans to define a path forward for ampreloxetine through discussions with regulators and strategic partners.
- Company continues to execute against business plan.
- Company remains disciplined in capital allocation.
- Company is on track to become sustainably cash-flow positive by the second half of 2022.
- Company plans to unlock value from pipeline throughout 2022.
Headline financials
Revenue & EPS history
Theravance · Revenue · Quarterly
$13.2M
Revenue by segment
Theravance · $19.4K total across 1 segment · Q3 2022
- YUPELRI$19.4K—100.0%
Forward guidance
Theravance Biopharma expects to become sustainably cash-flow positive by the second half of this year and going forward on an annual basis.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
-0.4%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+0.5%
Avg return
30 days after
53%
26 / 49 earnings
Positive
+22.6%
Q3 2025
Best reaction
-20.0%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.9% | +2.0% | — | |
| Q1 2026 | +0.4% | -2.8% | -3.8% | |
| Q3 2025 | +22.6% | +15.3% | +17.2% | |
| Q2 2025 | +4.2% | +14.2% | +20.0% | |
| Q1 2025 | -9.0% | -15.1% | +13.6% | |
| Q4 2024 | +2.1% | +0.2% | +1.7% | |
| Q3 2024 | +6.6% | +4.8% | +8.7% | |
| Q2 2024 | -18.8% | -20.5% | -16.6% | |
| Q1 2024 | +0.1% | -1.0% | -7.9% | |
| Q4 2023 | +7.9% | +5.1% | +0.3% | |
| Q3 2023 | +2.8% | +1.3% | +6.3% | |
| Q2 2023 | -2.1% | +0.2% | -4.0% | |
| Q1 2023 | +0.4% | -0.3% | -1.4% | |
| Q4 2022 | +9.4% | +2.0% | +8.6% | |
| Q3 2022 | +4.0% | +13.2% | +7.4% | |
| Q2 2022 | -5.4% | -2.6% | +1.4% | |
| Q1 2022 | -9.5% | -10.5% | -12.0% | |
| Q4 2021 | +6.3% | +7.8% | +4.0% | |
| Q3 2021 | +7.1% | +12.7% | -2.1% | |
| Q2 2021 | -5.9% | -5.9% | -36.4% | |
| Q1 2021 | -1.5% | -0.6% | -15.6% | |
| Q4 2020 | -3.3% | -8.4% | +10.7% | |
| Q3 2020 | -13.4% | -3.6% | -12.0% | |
| Q2 2020 | -11.9% | -15.8% | -15.8% | |
| Q1 2020 | -2.5% | +3.8% | -6.7% | |
| Q4 2019 | -10.5% | +0.6% | +0.7% | |
| Q3 2019 | +0.9% | +3.3% | +23.3% | |
| Q2 2019 | +6.4% | -0.1% | +10.8% | |
| Q1 2019 | -11.8% | -12.8% | -37.8% | |
| Q4 2018 | +1.0% | -0.5% | -7.0% | |
| Q3 2018 | -1.5% | +7.5% | +14.1% | |
| Q2 2018 | +17.3% | +20.3% | +21.0% | |
| Q1 2018 | +5.4% | +7.2% | +1.1% | |
| Q4 2017 | -8.4% | +0.7% | -15.7% | |
| Q3 2017 | -4.3% | -0.7% | -10.6% | |
| Q2 2017 | -20.0% | -19.3% | +3.8% | |
| Q1 2017 | +1.5% | -4.6% | -3.4% | |
| Q4 2016 | +1.0% | +5.9% | +22.2% | |
| Q3 2016 | +17.6% | +32.1% | +17.6% | |
| Q2 2016 | +3.0% | +6.2% | +15.6% | |
| Q1 2016 | +5.1% | — | — | |
| Q4 2015 | -0.3% | — | — | |
| Q3 2015 | -1.5% | — | — | |
| Q2 2015 | +0.4% | — | — | |
| Q1 2015 | +3.0% | — | — | |
| Q4 2014 | -6.9% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | -7.5% | — | — | |
| Q1 2014 | -2.6% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro